ABUS vs. OGN, MIRM, AMRX, IBRX, XENE, BHC, GMTX, APLS, ARWR, and TWST
Should you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Amneal Pharmaceuticals (AMRX), ImmunityBio (IBRX), Xenon Pharmaceuticals (XENE), Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry.
Arbutus Biopharma vs. Its Competitors
Organon & Co. (NYSE:OGN) and Arbutus Biopharma (NASDAQ:ABUS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.
Organon & Co. presently has a consensus price target of $18.00, indicating a potential upside of 79.64%. Arbutus Biopharma has a consensus price target of $5.50, indicating a potential upside of 72.96%. Given Organon & Co.'s higher probable upside, analysts clearly believe Organon & Co. is more favorable than Arbutus Biopharma.
Organon & Co. has higher revenue and earnings than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 1.4% of Organon & Co. shares are held by company insiders. Comparatively, 20.3% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Organon & Co. has a net margin of 11.92% compared to Arbutus Biopharma's net margin of -1,196.64%. Organon & Co.'s return on equity of 227.43% beat Arbutus Biopharma's return on equity.
Organon & Co. has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.
In the previous week, Organon & Co. had 42 more articles in the media than Arbutus Biopharma. MarketBeat recorded 44 mentions for Organon & Co. and 2 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.37 beat Organon & Co.'s score of 0.10 indicating that Arbutus Biopharma is being referred to more favorably in the news media.
Summary
Organon & Co. beats Arbutus Biopharma on 11 of the 17 factors compared between the two stocks.
Get Arbutus Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arbutus Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:ABUS) was last updated on 7/2/2025 by MarketBeat.com Staff
